Stock screener

GLUE

Conviction 100HealthcareScan · Thu, Jun 25, 2026
GLUE$21.67+3.91%
ResistanceSupportVol 14Insider sell
63 bars
3
2
2
Vol MA14 1.67M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Monte Rosa Therapeutics, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.monterosatx.com
Price21.67
Change+3.91%
Gap+0.65%
Rel volume4.11×
Avg volume1.47M
Avg $ vol27.97M
SMA 2018.39
SMA 5018.90
SMA 20016.15
Price vs 50+14.62%
Price vs 200+34.12%
MA stackbullish
50/200 cross
Supertrendup · 17.31
RSI (14)70
MACD hist0.47
MACD crossbull · 6d
Stoch %K / %D90 / 87
ADX (14)26
+DI / −DI31 / 10
RSI divergence
MACD divergenceBullish
ATR %+6.09%
ADR %6.95%
52w high25.31
52w low4.19
From 52w high-14.40%
Above 52w low+417.06%
New 52w highNo
SqueezeOff
Bollinger width32.11%
%B1.05
Donchian pos89.74%
Donchian high22.30
Donchian low16.11
AVWAP (52w high)19.35
vs AVWAP high+11.96%
AVWAP (52w low)15.68
vs AVWAP low+38.14%
OBV trendUp
Chaikin MF (20)0.03
Today vs 20d4.11×
Avg vol (14d)1.67M
Avg vol (20d)1.47M
Avg $ vol (20d)27.97M
Market cap1.83B
RS 3m (vs SPY)+29.39%
RS 6m (vs SPY)+26.43%
RS line new highNo
Trend template8/8
Technical rank89.9
1 week+17.68%
1 month+12.84%
3 months+37.91%
6 months+33.82%
1 year+357.07%
YTD+41.51%
P/E-47.38
P/B3.51
P/S14.80
P/FCF-66.56
EPS-2.96
Div yield
ROE-7.40%
ROA-5.24%
Debt/Eq
Current9.54
EV/EBITDA
Gross margin
Net margin-31.23%
Rev growth63.54%
EPS growth46.87%
Price target33.50
Target upside54.63%
Analyst ratingBuy
Institutional105.94%
Ent. value1.67B
Revenue4.21M
Net income-44.5M
Gross profit
Free cash flow-27.5M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out84.48M
Employees161
ListedThu, Jun 24, 2021
Free float49.32M
Float %75.7%
Short interest16.01M
Days to cover19.2d
Short volume63.0%
Squeeze score95 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$0.25 · 3 est
Last EPS vs est−$0.45 vs −$0.28
Last surprise-60.7% miss
Setup gradeA+
Conviction100 / 100
Pattern quality
Tech rank89.9 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance21.00
Support16.77
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in GLUE

All disclosures →
No recent disclosed trades by Congress in GLUE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in GLUE · 3 buys · 7 sells

InsiderSideShares
Janku Filip
Chief Medical Officer · Common Stock · 2026-06-24
Sell30K
Janku Filip
Chief Medical Officer · Common Stock · 2026-06-24
Exercise30K
Janku Filip
Chief Medical Officer · Stock Option (Right to Buy) · 2026-06-24
Exercise30K
Janku Filip
Chief Medical Officer · Common Stock · 2026-06-23
Sell11.85K
Champoux Jennifer
Chief Operating Officer · Common Stock · 2026-06-23
Exercise2.17K
Janku Filip
Chief Medical Officer · Stock Option (Right to Buy) · 2026-06-23
Exercise6K
Townson Sharon
Chief Scientific Officer · Common Stock · 2026-06-23
Exercise3K
Townson Sharon
Chief Scientific Officer · Common Stock · 2026-06-23
Sell3K
Champoux Jennifer
Chief Operating Officer · Common Stock · 2026-06-23
Sell2.17K
Townson Sharon
Chief Scientific Officer · Stock Option (Right to Buy) · 2026-06-23
Exercise3K

SEC filings

EDGAR filings in GLUE · 8 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.